Low-Buffer Peptide Compositions for Room-Temperature Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing peptide formulations are unstable at room temperature and require refrigeration, often containing high levels of stabilizers and preservatives that can cause undesired side effects.
Innovation Solution
A stable, dilute peptide composition comprising low levels of EDTA and citrate buffer, with optional surfactants like tyloxapol, maintains peptide stability at room temperature without refrigeration, reducing the need for stabilizers and preservatives.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If peptide compositions are formulated with high levels of stabilizers and preservatives to maintain stability, then the stability and shelf life are improved, but undesired side effects and toxicity increase
Solution Approach 1:
The patent changes the concentration parameters of stabilizers and preservatives from high levels to low levels (e.g., EDTA at 0.001-0.1%, citrate at 0.01-1%, tyloxapol at 0.001-0.1%), achieving peptide stability while minimizing harmful side effects and toxicity in sensitive areas like the eye
Solution Approach 2:
The patent uses a composite formulation combining multiple low-concentration components (EDTA, citrate buffer, tyloxapol surfactant, and peptide) that work synergistically to stabilize the peptide without requiring high levels of individual stabilizers or preservatives, thereby reducing adverse reactions
2Reliability
If peptide compositions require refrigeration to maintain stability, then peptide degradation is reduced, but ease of operation and patient compliance deteriorate
Solution Approach 1:
The patent changes the storage temperature parameter from refrigerated (2-8°C) to room temperature (20-25°C) by optimizing the formulation with low levels of stabilizers and preservatives, eliminating the need for cold chain storage and improving patient compliance and ease of operation
Solution Approach 2:
The peptide composition is formulated to be self-stabilizing at room temperature through the synergistic action of low-concentration EDTA, citrate buffer, and tyloxapol, without requiring external refrigeration or special storage conditions
3Reliability
If peptide compositions are formulated as concentrated solutions, then therapeutic efficacy is improved, but stability and ease of administration deteriorate
Solution Approach 1:
The patent optimizes the concentration parameter of the peptide to a low range (0.001-0.1%), which maintains composition stability and reduces aggregation while still providing therapeutic efficacy when applied topically to sensitive areas like the eye
Solution Approach 2:
The patent uses dilute peptide compositions that are stable at room temperature, creating a simplified version that maintains therapeutic benefit while eliminating the need for complex refrigerated storage and reconstitution procedures
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition maintains peptide integrity and efficacy over prolonged periods, allowing for long-term storage and reduced adverse reactions, while being suitable for topical application in sensitive areas like the eye.
Implementation Method 1
about 0.0001%-0.01% (e.g., 0.001%) disodium EDTA
Implementation Method 2
about 0.03%-3% (e.g., 0.2888%) of a buffer; wherein the pH of the composition is between about 6.2 to about 6.8
Implementation Method 3
no, or about 0.005%-0.5% (e.g., 0%, or 0.05%) tyloxapol
Data Source
AI summary
This application generally relates to stable peptide compositions and kits comprising low levels of buffering and chelating agents, and methods of using the same.